FDA cleared the InQwire Super Stiff Guide Wire (IQSS32180J3); InQwire Super Stiff Guide Wire (IQSS35F260S); InQwire Super Stiff Guide Wire (IQSS35F150S); InQwire Super Stiff Guide Wire (IQSS35F100S); InQwire Super Stiff Guide Wire (IQSS35F80S); InQwire Super Stiff Guide Wire (IQSS35F180S) from Merit Medical Ireland, Ltd. on Jan 21, 2026 under K251385, a traditional 510(k). The device falls under product code DQX, Wire, Guide, Catheter, regulated at 21 CFR 870.1330 as a Class 2 device. The review panel was Cardiovascular.
FDA logged the submission as received on May 5, 2025. The decision came 261 days later, longer than the 90 FDA-day review goal, which usually means at least one additional information request.
Merit Medical Ireland, Ltd. has 3 other decisions in the tracker over the last 12 months: K261640 (Merit MAK Nitinol/Gold-Tungsten Guide Wire), K254137 (InQwire Amplatz Guide Wire), K253847 (Splashwire Hydrophilic Guide Wire (MSWSTD35150J3)).
Questions & Answers
What did FDA clear under K251385?
K251385 is the FDA 510(k) for InQwire Super Stiff Guide Wire (IQSS32180J3); InQwire Super Stiff Guide Wire (IQSS35F260S); InQwire Super Stiff Guide Wire (IQSS35F150S); InQwire Super Stiff Guide Wire (IQSS35F100S); InQwire Super Stiff Guide Wire (IQSS35F80S); InQwire Super Stiff Guide Wire (IQSS35F180S), submitted by Merit Medical Ireland, Ltd.. FDA's decision date was Jan 21, 2026, under product code DQX (Wire, Guide, Catheter).
Who makes the InQwire Super Stiff Guide Wire (IQSS32180J3); InQwire Super Stiff Guide Wire (IQSS35F260S); InQwire Super Stiff Guide Wire (IQSS35F150S); InQwire Super Stiff Guide Wire (IQSS35F100S); InQwire Super Stiff Guide Wire (IQSS35F80S); InQwire Super Stiff Guide Wire (IQSS35F180S)?
Merit Medical Ireland, Ltd., based in Galway, is the applicant of record for K251385.
How long did the K251385 review take?
FDA received the submission on May 5, 2025 and issued its decision on Jan 21, 2026, 261 days later.